Home
News
Media
All VideosClinical Trials in ProgressImmunoLogicNews Network
Partners
More
CME/CE
Conferences
Sponsored

Subscribe

  • Home
  • News
  • Media
    • Partners
    • CME/CE
    • Conferences
    • Sponsored
    • Subscribe
    • Cardiology
    • Dermatology
    • Endocrinology
    • Hematology
    • Lysosomal Disorders
    • Neurology
    • Oncology
    • Ophthalmology
    Advertisement

    Sarah Pressman Lovinger, MD

    Advertisement

    Articles by Sarah Pressman Lovinger, MD

    Orthopedists Consider Gene Therapy, Stem Cells for Bone Injuries

    BySarah Pressman Lovinger, MD
    June 3rd 2007
    Advertisement

    Latest Updated Articles

    • Uptake of Nononcology Gene Therapy Remains Slow in Hematology
      Uptake of Nononcology Gene Therapy Remains Slow in Hematology

      Published: August 16th 2024 | Updated: August 19th 2024

    • Phase 3 Trial Seeks to Continue Supporting Arsa-Cel Gene Therapy for MLD
      Phase 3 Trial Seeks to Continue Supporting Arsa-Cel Gene Therapy for MLD

      Published: March 18th 2024 | Updated: June 3rd 2024

    • Peter A. Riedell, MD, from the David and Etta Jonas Center for Cellular Therapy, University of Chicago
      Rapcabtagene Autoleucel Shows Promise for DLBCL in Updated Phase 2 Data

      Published: December 7th 2024 | Updated:

    • Aimee C. Talleur, MD
      Aimee C. Talleur, MD, on Predicting Response and Toxicity to Cell Therapy

      Published: December 12th 2022 | Updated:

    •  David Telander, MD, Ph
      RPE Cell Therapy Shows Improvements in Early GA With AMD

      Published: July 14th 2024 | Updated:

    • Multi-Characteristic Opsin Gene Therapy for Retinitis Pigmentosa Improves Multiple Measures of Vision
      Multi-Characteristic Opsin Gene Therapy for Retinitis Pigmentosa Improves Multiple Measures of Vision

      Published: May 18th 2023 | Updated:



    Advertisement
    Advertisement

    Trending on CGTlive®

    1

    Sanofi’s Neovascular Age-Related Macular Degeneration Gene Therapy SAR402663 Garners FDA Fast Track Designation

    2

    Ultragenyx's Glycogen Storage Disease Gene Therapy DTX401 Continues to Enable Decreases in Reductions in Daily Cornstarch Intake at 96 Weeks

    3

    Around the Helix: Cell and Gene Therapy Company Updates – September 17, 2025

    • About Us
    • Editorial
    • Contact Us
    • Terms and Conditions
    • Do Not Sell My Information
    • Privacy
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Monroe, NJ 08831

    609-716-7777

    • HCP Live
    • Contagion Live
    • CGT Live
    • Neurology Live
    • Oncology Live
    • Contemporary Pediatrics
    • Contemporary OBGYN
    • Urology Times
    • The Educated Patient
    HCP Live
    Brand Logo

    © 2025 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us